Kern, Kenneth A.
Pfizer (United States)
3 papers on CoChatORCID 0009-0002-8125-1727
Most cited papers
- Verified
A Phase I, Dose-Finding Study in Patients with Advanced Solid Malignancies of the Oral γ-Secretase Inhibitor PF-03084014
Messersmith, W. A., Shapiro, G. I., Cleary, J. M., Jimeno, A., Dasari, A., Huang, B., Shaik, M. N., Cesari, R., Zheng, X., Reynolds, J. M., et al. (2015) · Clinical Cancer Research
Alzheimer's disease research and treatmentsWnt/β-catenin signaling in development and cancer
Cited by 218
- Verified
A Phase 1 study of the novel gamma‐secretase inhibitor PF‐03084014 in patients with T‐cell acute lymphoblastic leukemia and T‐cell lymphoblastic lymphoma
Papayannidis, C., DeAngelo, D. J., Stock, W., Huang, B., Shaik, M. N., Cesari, R., Zheng, X., Reynolds, J. M., English, P. A., Ozeck, M., et al. (2015) · Blood Cancer Journal
Acute Lymphoblastic Leukemia researchChronic Lymphocytic Leukemia Research
Cited by 122
- Verified
A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer
Wainberg, Z. A., Alsina, M., Soares, H. P., Braña, I., Britten, C. D., Del Conte, G., Ezeh, P., Houk, B., Kern, K. A., Leong, S., et al. (2017) · Targeted Oncology
PI3K/AKT/mTOR signaling in cancerColorectal Cancer Treatments and Studies
Cited by 98
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free